BiotechTube
Sixera Pharma

Sixera Pharma

Stockholm, Sweden· Est.
sixerapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Sixera Pharma is a private, pre-revenue biotech company developing SXR1096, a potential first-in-class topical treatment for Netherton syndrome. The company leverages foundational research by its founders on kallikrein-related peptidases (KLKs) in skin barrier function. Having initiated its first clinical trial in 2021 and secured FDA Rare Pediatric Disease Designation in 2022, Sixera represents a focused effort to address a high-unmet medical need in a rare disease niche. Its development is supported by a network of academic and industrial collaborations.

DermatologyRare Genetic Diseases

Technology Platform

Research platform focused on kallikrein-related peptidases (KLKs) and protease inhibition in skin barrier function, specifically targeting the underlying pathophysiology of Netherton syndrome.

Opportunities

As a potential first-in-class therapy for a severe, untreated rare disease, SXR1096 could achieve premium pricing and rapid adoption.
The FDA's Rare Pediatric Disease Designation provides a valuable priority review voucher upon approval, which is a significant financial asset.
Success in Netherton syndrome could pave the way for exploring the platform in more common dermatological conditions with similar pathophysiology.

Risk Factors

The company faces high clinical development risk with its first-in-human asset.
Its financial sustainability is uncertain as a private, pre-revenue company reliant on external funding.
The ultra-rare patient population presents commercialization challenges that may require a partnership or acquisition to address effectively.

Competitive Landscape

The competitive landscape for Netherton syndrome is nascent, with no approved targeted therapies. Competition may emerge from other companies developing KLK inhibitors for broader dermatology indications like atopic dermatitis, who could later pursue NS. Sixera's deep, founder-led expertise in the specific NS mechanism provides a potential first-mover advantage.

More companies in Small Molecule Drugs →More companies in Sweden →